Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RayzeBio, Inc. · GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor
Phase 3
Recruiting
338
2026-03
Industry sponsor intelligence
RayzeBio, Inc.Clinical Pipeline.
Lead-sponsor view of RayzeBio, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 1
- Active
- 0
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 338
Pipeline overview
Programs by phase and activity.
Velocity
RayzeBio, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Lanreotide → | 1 | 0 | 0 | 1 | 0 | 1 |
| Octreotide → | 1 | 0 | 0 | 1 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All RayzeBio, Inc. studies.
This page groups studies where RayzeBio, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first